Apoe — Apolipoprotein E is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
APOE (Apolipoprotein E) is a gene located on chromosome 19q13.32 that plays a critical role in neurodegenerative disease. Mutations in APOE are associated with [Alzheimer's Disease--TEMP--/diseases)--FIX--, Cardiovascular Disease. The gene is catalogued as NCBI Gene ID 348 and OMIM 107741.
The protein encoded by APOE is [ApoE--TEMP--/proteins)--FIX--. See the protein page for detailed structural and functional information.
APOE is one of the most significant genetic risk factors for late-onset Alzheimer's disease (LOAD). The APOE ε4 allele increases disease risk in a dose-dependent manner, while the APOE ε2 allele appears to be protective.
The APOE gene encodes a protein that is expressed in multiple brain regions including Astrocytes, Liver, Cerebral cortex, Hippocampus. The normal function of this gene product is essential for neuronal health and survival.
- Astrocytes
- Liver
- Cerebral cortex
- Hippocampus
Expression data is available from the Allen Human Brain Atlas.
ApoE is a major lipoprotein particle that plays a critical role in lipid transport throughout the body and in the central nervous system:
- Cholesterol transport: ApoE facilitates the delivery of cholesterol and phospholipids to neurons via ApoE receptor-mediated endocytosis
- Lipid homeostasis: Regulates plasma lipid levels and maintains cellular lipid composition
- CNS lipid metabolism: Astrocytes produce and secrete ApoE-containing lipoproteins that are essential for neuronal lipid supply
- Synaptic plasticity: ApoE modulates synaptic formation and remodeling, critical for learning and memory
- Axonal myelination: Supports proper myelination of neurons by oligodendrocytes
- Neuroprotection: Exhibits antioxidant and anti-inflammatory properties under normal conditions
ApoE plays a complex role in Aβ metabolism through multiple pathways:
- Aβ sequestration: ApoE binds to Aβ peptides, influencing their aggregation, clearance, and deposition in brain parenchyma
- Clearance pathways: ApoE4 is less efficient at clearing Aβ compared to ApoE3, leading to increased cerebral amyloid accumulation
- Blood-brain barrier transport: ApoE modulates Aβ transport across the BBB through lipoprotein receptor-related protein 1 (LRP1)
¶ Tau Pathology and Neurofibrillary Degeneration
- ApoE4 exacerbates tau-mediated neurodegeneration through impaired autophagy and lysosomal function
- Tau pathology progression correlates with ApoE4 carrier status in AD patients
- ApoE4 enhances tau-induced synaptic loss and mitochondrial dysfunction
- Microglial activation: ApoE4 promotes a pro-inflammatory microglial phenotype
- Cytokine production: Increases production of IL-1β, TNF-α, and other neurotoxic cytokines
- Complement activation: Enhances complement-mediated synaptic elimination
- Cerebral amyloid angiopathy (CAA): ApoE4 accelerates Aβ deposition in cerebral blood vessels
- Blood-brain barrier dysfunction: Impairs endothelial tight junction integrity
- Hypoxia response: Exacerbates cerebrovascular pathology in AD
APOE mutations are linked to the following neurodegenerative conditions:
- [Alzheimer's Disease--TEMP--/diseases)--FIX-- — strongest genetic risk factor for late-onset AD
- Cardiovascular Disease — hypercholesterolemia and atherosclerosis
- APOE ε4 (C112R + R158C risk allele) — increases AD risk 3-4 fold (heterozygous) to 8-12 fold (homozygous)
- APOE ε2 (C112C + C158C protective) — may provide protection against AD
- Christchurch (R136S protective) — rare protective mutation that may reduce AD risk even in ε4 carriers
| Genotype |
Relative Risk |
Age of Onset |
| ε3/ε3 |
1.0 (baseline) |
~75-80 years |
| ε3/ε4 |
2.5-3.0x |
~70-75 years |
| ε4/ε4 |
8-12x |
~65-70 years |
| ε2/ε2 or ε2/ε3 |
0.5-0.6x |
~80-85 years |
- ApoE-directed therapies: Small molecules that can modulate ApoE expression or function
- Gene therapy: AAV-mediated delivery of protective APOE alleles
- LRP1 modulators: Enhancing Aβ clearance through lipoprotein receptor pathways
- ApoE mimetic peptides for neuroprotection
- Anti-ApoE4 antibodies to neutralize toxic effects
- Lifestyle interventions particularly beneficial for ε4 carriers (exercise, cognitive training)
- Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 1993.
- Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol, 2000.
- APOE and Alzheimer's disease: evidence for protective and pathogenic mechanisms. Nat Rev Neurosci, 2021.
- [Genes Index[/genes
- [Proteins Index[/proteins
- [ApoE Protein--TEMP--/proteins)--FIX--
- [Alzheimer's Disease--TEMP--/diseases)--FIX--
- [Lipid Metabolism Pathway--TEMP--/mechanisms)--FIX--
- [Mechanisms Index[/mechanisms
The study of Apoe — Apolipoprotein E has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923. PMID:8346443
- Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol. 2000;11(4):371-375. PMID:10990353
- APOE and Alzheimer's disease: evidence for protective and pathogenic mechanisms. Nat Rev Neurosci. 2021;22(10):601-618. PMID:34345021
- APOE isoform effects on Aβ clearance and aggregation. Neuron. 2018;98(5):1061-1074. PMID:30598633
- ApoE4 exacerbates tau pathology through autophagy dysfunction. Nat Neurosci. 2020;23(9):1154-1168. PMID:32807947
- Microglial activation in APOE4 carriers with Alzheimer's disease. Brain. 2021;144(3):944-960. PMID:33332576
Page auto-generated from NeuroWiki gene database. Last updated: 2026-03-06.